PLAINSBORO, NJ, USA I May 2, 2025 I Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application ...

CAMBRIDGE, MA, USA I May 01, 2025 I Kronos Bio, Inc. (“Kronos Bio”) (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases ...

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD ...

MELBOURNE, Australia and PRINCETON, NJ, USA I April 30, 2025 I Dimerix Limited (ASX: DXB, “Dimerix”) and Amicus Therapeutics (Nasdaq: FOLD, “Amicus”) today announced that the two companies have ...

PHILADELPHIA, PA, USA I April 30, 2025 I Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific ...

PLAINSBORO, NJ, USA I April 30, 2025 I Today, The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which investigated the effects of ...

SHANGHAI, China I April 30, 2025 I Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in poster ...

OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop ...

PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory ...

SOUTH SAN FRANCISCO, CA, USA I April 30, 2025 I Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus ...